RVPH REVIVA PHARMACEUTICALS HLDGS INC

Reviva to Participate in the A.G.P. Healthcare Company Showcase

Reviva to Participate in the A.G.P. Healthcare Company Showcase

CUPERTINO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the A.G.P. Healthcare Company Showcase, taking place virtually May 21, 2025.

A.G.P. Healthcare Company Showcase

Format: Fireside Chat

Date: Wednesday, May 21, 2025

Time: 2:00 p.m. EST

Location: Virtual

Webcast Link:

About Reviva 

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:

Reviva Pharmaceuticals Holdings, Inc.

Laxminarayan Bhat, PhD 

Investor Relations Contact:

LifeSci Advisors, LLC

Bruce Mackle



EN
13/05/2025

Underlying

RVPHREVIVA PHARMACEUTICALS HLDGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REVIVA PHARMACEUTICALS HLDGS INC

 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspect...

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking pla...

June 5, 2025 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open...

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia – Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Brilaroxazine improved multiple neuroinflammatory markers reported to enhance efficacy and mitigate side effects – – Virtual investor webcast today at 8:00 a.m. EDT – CUPERTINO, Calif., June 02, 2025 (GLOBE NEWSWIRE) --  Reviva ...

June 2, 2025 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva to Participate in Upcoming Investor Conferences in May 2025

Reviva to Participate in Upcoming Investor Conferences in May 2025 CUPERTINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following upcoming investor conferences. Benchmark Healthcare House Call Virtual Investor Confere...

May 20, 2025 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva Reports First Quarter 2025 Financial Results and Recent Busines...

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights – 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment – – Full data set from RECOVER OLE highlighting clinical response, safety, efficacy, adherence, and biomarker data expected in Q2 2025 – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 – CUPERTINO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or th...

May 15, 2025 1 EN
 PRESS RELEASE
Free
RVPH REVIVA PHARMACE...

Reviva to Participate in the A.G.P. Healthcare Company Showcase

Reviva to Participate in the A.G.P. Healthcare Company Showcase CUPERTINO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the A.G.P. Healthcare Company Showcase, taking place virtually May 21, 2025. A.G.P. H...

May 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch